Insights
Search Results
Client Highlights
3.17.26
Firm Advises R1 Therapeutics on $77.5 Million Series A Financing
On March 17, 2026, R1 Therapeutics, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc., with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. Wilson Sonsini Goodrich & Rosati advised R1 on the financing.
Client Highlights
1.12.26
Firm Advises SR One on AirNexis Therapeutics’ $200 Million Series A
On January 9, 2026, AirNexis Therapeutics, a clinical-stage biotech company developing therapeutics for pulmonary diseases, announced the close of a $200 million Series A financing round and the in-license of a dual PDE3/4 inhibitor in Phase 2 development for chronic obstructive pulmonary disease (COPD) from Haisco Pharmaceutical Group. The over-subscribed Series A was led by Frazier Life Sciences, with participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital, and Enavate Sciences, among others. Wilson Sonsini Goodrich & Rosati advised investor SR One on the financing transaction.
Proceeds from the Series A will fund the global clinical development of AN01. Also known as HSK39004, AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors. This MOA may lead to improvements in airflow limitation and airway inflammation, supporting the maintenance treatment of COPD.
The Wilson Sonsini team that advised SR One was led by Dan Koeppen, with support from Kassandra Castillo and Tim Conroy.
Proceeds from the Series A will fund the global clinical development of AN01. Also known as HSK39004, AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through a dual mechanism of action (MOA) that promotes bronchodilation and reduces the release of inflammatory factors. This MOA may lead to improvements in airflow limitation and airway inflammation, supporting the maintenance treatment of COPD.
The Wilson Sonsini team that advised SR One was led by Dan Koeppen, with support from Kassandra Castillo and Tim Conroy.
Client Highlights
2.20.25
Wilson Sonsini Advises Versant Ventures and OrbiMed on Helicore Biopharma's $65 Million Series A
On January 28, 2025, Helicore Biopharma, a biopharmaceutical company focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions, emerged from stealth with $65 million in Series A financing. The round was co-led by founding investor Versant Ventures and by OrbiMed, with participation from Longitude Capital and Wellington Management. Wilson Sonsini Goodrich & Rosati advised Versant Ventures and OrbiMed on the transaction.
Client Highlights
2.18.25
Wilson Sonsini Advises Esperto Medical on Oversubscribed Series A
On February 18, 2025, Esperto Medical™, a healthtech start-up specializing in critical care and remote patient monitoring, announced the closing of an oversubscribed Series A investment round co-led by Catalyst Health Ventures and Bold Capital Partners, with support from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures. Wilson Sonsini Goodrich & Rosati advised Esperto on the transaction.
Client Highlights
1.17.24
Wilson Sonsini Advises Cleveland Diagnostics on $75 Million Growth Capital Financing
On January 17, 2024, Cleveland Diagnostics, a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced the closing of over $75 million in growth capital financing led by Novo Holdings with participation from existing investors as well as a credit facility from Symbiotic Capital. Wilson Sonsini Goodrich & Rosati represented Cleveland Diagnostics on the transaction.
Client Highlights
4.25.23
Wilson Sonsini Advises Voluware on Investment from Hughes & Company
On April 17, 2023, Voluware, an award-winning provider of solutions to speed and simplify prior authorizations, announced a capital investment from Hughes & Company. The additional capital will accelerate the company's product innovation and devote more resources to expanding payer coverage and geographic footprint, and client onboarding and support. With growing interest in Voluware from providers of revenue cycle management and electronic medical record solutions, the additional capital will also enable Voluware to acquire and support more partnerships and resellers for its prior authorization products.
Client Highlights
6.22.22
Boehringer Ingelheim Signs Option to Acquire Trutino Biosciences
On June 14, 2022, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire Trutino Biosciences Inc., a San Diego-based pre-clinical stage biotech company dedicated to the discovery and development of next-generation cytokine therapies to treat immuno-oncology and autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences in the transaction.
Client Highlights
5.18.22
Wilson Sonsini Advises Infinitum Electric on $80 Million Series D
On May 17, 2022, Infinitum Electric, a company creating a sustainable, air-core motor, announced $80 million in Series D funding to scale motor production to meet increasing demand. Infinitum Electric’s patented air-core motor design replaces heavy iron used in traditional motors with a lightweight, printed circuit board to generate the same power in half the size and weight, at a fraction of the noise and carbon footprint created by conventional motors. Infinitum Electric will use the investment to vertically integrate and automate production of its motors for the commercial and industrial market segments, and complete development and commercialization of a traction motor for the rapidly growing electric vehicle market, where its breakthrough power density can significantly extend the range of electric vehicles. Wilson Sonsini Goodrich & Rosati represented Infinitum Electric in the transaction.
Client Highlights
1.27.22
Wilson Sonsini Advises SR One on Corporate, IP Matters Related to Simcha Therapeutics’ $40 Million Series B Financing
On January 27, 2022, Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40 million Series B financing. The round was led by SR One Capital Management and joined by other new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital. Wilson Sonsini Goodrich & Rosati advised SR One on corporate and IP matters related to the transaction.
Client Highlights
9.10.21
Wilson Sonsini Advises Logos Capital on Attralus' $116 Million Series B
On September 8, 2021, Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $116 million Series B financing. The financing round was led by Logos Capital and included participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. Founding investor venBio Partners also participated in the financing. Wilson Sonsini Goodrich & Rosati represented Logos Capital in the transaction.
Client Highlights
9.17.20
Wilson Sonsini Represents NiKang Therapeutics in $50 Million Series B Financing
On September 14, 2020, NiKang Therapeutics, an early stage biotech company focused on developing novel small molecule oncology drug discovery, announced the completion of a Series B financing for $50 million. The financing was led by RTW Investments, LP, with additional support from existing investor CBC Group, and from new investors including Lilly Asia Ventures, Casdin Capital, HBM Healthcare Investments, Matrix Partners China, and Octagon Capital. Wilson Sonsini Goodrich & Rosati advised NiKang Therapeutics in the transaction.
Client Highlights
12.31.19
Elevar Therapeutics Completes Merger Transaction with South Korean Company HLB
On November 27, 2019, Elevar Therapeutics completed its merger transaction with HLB, a South Korean company whose shares are publicly traded on the Korean stock exchange, pursuant to which Elevar became a wholly-owned subsidiary of HLB. Elevar is a pharmaceutical company based primarily in Utah specializing in clinical development of promising therapies for unmet medical needs in cancer. Wilson Sonsini acts as patent, corporate and technology transactions counsel for Elevar, including in connection with the merger transaction.